A meta-analysis of the efficacy and safety of recombinant activated factor VII for patients with acute intracerebral hemorrhage without hemophilia

@article{Yuan2010AMO,
  title={A meta-analysis of the efficacy and safety of recombinant activated factor VII for patients with acute intracerebral hemorrhage without hemophilia},
  author={Z. H. Yuan and J. K. Jiang and W. D. Huang and J. Pan and J. Wang},
  journal={Journal of Clinical Neuroscience},
  year={2010},
  volume={17},
  pages={685-693}
}
  • Z. H. Yuan, J. K. Jiang, +2 authors J. Wang
  • Published 2010
  • Medicine
  • Journal of Clinical Neuroscience
  • Hematoma growth is common in intracerebral hemorrhage (ICH) and is associated with a poor outcome for patients. To evaluate the efficacy and safety of recombinant activated factor VII (rFVIIa) used as a hemostatic agent in patients with ICH without hemophilia, we searched Medline, Scopus, the Cochrane Library, Clinicaltrials.gov and the Stroke Trials Directory. Five randomized controlled trials were selected for analysis. Although rFVIIa can reduce the change in ICH volume, there was no… CONTINUE READING

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    This study aims to determine whether in-bed cycle ergometry, early in the hospital course after a brain hemorrhage could balance damaging and reparative inflammation in the brain… Expand
    ConditionsIntra Cerebral Hemorrhage, Stroke Hemorrhagic
    InterventionDevice

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 38 REFERENCES
    Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage.
    • 945
    • PDF
    Measuring inconsistency in meta-analyses
    • 31,452
    • PDF
    Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage.
    • 529
    Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage.
    • 187